Yarrow Bioscience, Inc. — Form 8-K
Filed July 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Effective July 27, 2026, VYNE Therapeutics Inc. changed its corporate name to Yarrow Bioscience, Inc., and executed a 1-for-50 reverse stock split (effective July 24, 2026). The company also adopted amended and restated certificates of incorporation and bylaws. Concurrently, pre-funded warrants with $0.0001 exercise price and a 2026 stock incentive plan were filed.
Why this rating
Name change and reverse split are routine restructuring events. No material business transaction, financing, or asset change disclosed. Small company size ($32M) makes structural filings less impactful relative to operations.
See more from July 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.